Probiotic yeast secreting single-domain antibodies to prevent Clostridium difficile and Campylobacter jejuni disease
益生菌酵母分泌单域抗体来预防艰难梭菌和空肠弯曲菌疾病
基本信息
- 批准号:10364713
- 负责人:
- 金额:$ 41.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-03-15 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:ADP Ribose TransferasesAffinityAlpacaAnimal ModelAnimalsAntibodiesBacterial InfectionsBindingBlocking AntibodiesCampylobacter jejuniCaspaseCell WallClinicalClostridium difficileDNA cassetteDeveloped CountriesDeveloping CountriesDevelopmentDiarrheaDiseaseDried YeastDrug resistanceEncapsulatedEngineeringEnteralEnterotoxinsFlagellaFormulationFundingFutureGenerationsGoalsHumanImmuneImmunizeIn VitroInfectionInflammatory Bowel DiseasesIntestinesLeadLibrariesMorbidity - disease rateMulti-Drug ResistanceMultiple Bacterial Drug ResistanceMusOral AdministrationPathogenesisPeptide HydrolasesPlayPreventionPrevention strategyPreventive measureProbioticsProcessRecurrenceResearchResearch Project GrantsRoleSaccharomycesSiteSorting - Cell MovementSurfaceTechnologyTestingToxinTranslational ResearchVaccinationVaccinesValidationVirulence FactorsWorkYeastsbasecapsulecell motilityclinical developmentcommercializationcross reactivityefficacy evaluationenteric pathogenglobal healthgut colonizationhomologous recombinationimmunological interventionimprovedin vivoinnovationlead candidatemortalitymulti-drug resistant pathogennanobodiesnovelpassive antibodiespathogenic bacteriapre-clinicalpreventprogramsprotective efficacyprototypescreening
项目摘要
Abstract
As multidrug-resistant (MDR) bacteria are increasingly difficult to treat and are associated with greater
morbidity and mortality, we are facing a global health crisis. Countermeasures that do not select for drug
resistance are urgently needed. The overall goal of this research program is to develop novel immune-based
preventive strategies against major MDR pathogens in developing and developed countries. In this project we
aim to develop novel probiotic yeast-based immune-interventions against Clostridium difficile and
Campylobacter jejuni, the major causes of bacterial diarrheal and intestinal inflammatory diseases worldwide.
We have developed a novel platform technology against these enteric pathogens by engineering a probiotic
yeast, Saccharomyces boulardii, to secrete multi-specific, single-domain antibodies directly targeting bacterial
virulence factors at the intestinal site of infection. Through our previously funded Centers of Excellence for
Translational Research (CETR) project, we have applied this technology to target C. difficile, and have already
generated a prototype yeast strain that constitutively secretes a tetra-specific, single-domain-antibody (VHH)
fusion which neutralizes the two major C. difficile enterotoxins TcdA and TcdB. A recently completed proof-of-
principle study has shown that oral administration protected mice from both primary and recurrent C. difficile
infection. Building upon these highly encouraging results, we propose to: 1) generate lead S. boulardii strains
secreting multi-specific antibodies against bacterial colonization factors of C. difficile and C. jejuni; 2)
preclinically evaluate the efficacy of the lead strains on reducing bacterial colonization and preventing disease
in animal models; and 3) develop a formulation for drying and encapsulating these lead yeast strains that is
compatible for future use in humans. We envision that our future final products for human use will be enteric
coated capsules containing dried yeast strains, similar to those probiotic S. boulardii products sold over-the-
counter. With the completion of proposed translational activities, we expect to generate a final improved
product of engineered yeast strains to prevent C. difficile disease and a prototype product to prevent C. jejuni
disease. Successful preclinical validation of the lead candidates will also allow further development and large-
scale efforts for eventual commercialization of these products against C. difficile and C. jejuni diseases, for
which we currently have no effective preventative measures.
摘要
由于多药耐药(MDR)细菌越来越难以治疗,并且与更大的
发病率和死亡率,我们正面临着一场全球健康危机。不选择毒品的对策
迫切需要抵抗。这项研究计划的总体目标是开发新的基于免疫的
发展中国家和发达国家针对主要MDR病原体的预防策略。在这个项目中,我们
旨在开发新的基于益生菌酵母的免疫干预措施,以对抗艰难梭菌,
空肠弯曲菌是世界范围内细菌性肠炎和肠道炎症性疾病的主要致病菌。
我们已经开发了一种新的平台技术,通过工程益生菌对抗这些肠道病原体
酵母菌布拉酵母(Saccharomyces boulardii)分泌直接靶向细菌的多特异性单结构域抗体
在肠道感染部位的毒力因子。通过我们以前资助的卓越中心,
翻译研究(CETR)项目,我们已经将这项技术应用于目标C。艰难,而且已经
产生了组成型分泌四特异性单结构域抗体(VHH)的原型酵母菌株,
核聚变反应中和了两个主要的碳原子。艰难梭菌肠毒素TcdA和TcdB。一个最近完成的证明-
主要研究表明口服给药保护小鼠免受原发性和复发性C.艰难
感染基于这些非常令人鼓舞的结果,我们建议:1)产生铅S。布拉氏菌
分泌针对C. difficile和C.空肠; 2)
临床前评价先导菌株减少细菌定植和预防疾病的有效性
在动物模型中;和3)开发用于干燥和包封这些先导酵母菌株的制剂,
未来可用于人类。我们设想,我们未来用于人类的最终产品将是肠溶的
包衣胶囊含有干燥的酵母菌株,类似于那些益生菌S。布拉地产品销售超过
柜台随着拟议翻译活动的完成,我们预计将产生一个最终的改进,
工程酵母菌株的产品,以防止C.艰难梭菌病和预防C.空肠
疾病对主要候选药物的成功临床前验证也将允许进一步开发和大规模应用。
规模化的努力,这些产品的最终商业化对C。difficile和C.空肠疾病,用于
目前我们还没有有效的预防措施。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hanping Feng其他文献
Hanping Feng的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hanping Feng', 18)}}的其他基金
Characterization of neutralizing antitoxins and epitopes in Clostridium difficile patients
艰难梭菌患者中和抗毒素和表位的特征
- 批准号:
10549285 - 财政年份:2020
- 资助金额:
$ 41.86万 - 项目类别:
Preventing norovirus and Clostridium difficile gastroenteritis by engineered probiotic yeast Saccharomyces boulardii secreting multi-specific single-domain antibodies
通过分泌多特异性单域抗体的工程益生菌布拉酵母菌预防诺如病毒和艰难梭菌胃肠炎
- 批准号:
10540345 - 财政年份:2020
- 资助金额:
$ 41.86万 - 项目类别:
Preventing norovirus and Clostridium difficile gastroenteritis by engineered probiotic yeast Saccharomyces boulardii secreting multi-specific single-domain antibodies
通过分泌多特异性单域抗体的工程益生菌布拉酵母菌预防诺如病毒和艰难梭菌胃肠炎
- 批准号:
10320907 - 财政年份:2020
- 资助金额:
$ 41.86万 - 项目类别:
Characterization of neutralizing antitoxins and epitopes in Clostridium difficile patients
艰难梭菌患者中和抗毒素和表位的特征
- 批准号:
10319522 - 财政年份:2020
- 资助金额:
$ 41.86万 - 项目类别:
Probiotic yeast secreting single-domain antibodies to prevent Clostridium difficile and Campylobacter jejuni disease
益生菌酵母分泌单域抗体来预防艰难梭菌和空肠弯曲菌疾病
- 批准号:
10584482 - 财政年份:2019
- 资助金额:
$ 41.86万 - 项目类别:
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection
一种抗艰难梭菌感染的新型人源化四特异性抗体
- 批准号:
10432036 - 财政年份:2017
- 资助金额:
$ 41.86万 - 项目类别:
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection
一种抗艰难梭菌感染的新型人源化四特异性抗体
- 批准号:
9362547 - 财政年份:2017
- 资助金额:
$ 41.86万 - 项目类别:
Toxemia and systemic disease in Clostridium difficile infection
艰难梭菌感染的毒血症和全身性疾病
- 批准号:
8664002 - 财政年份:2013
- 资助金额:
$ 41.86万 - 项目类别:
Epithelium, dendritic cells, and Clostridium difficile associated colitis
上皮、树突状细胞和艰难梭菌相关结肠炎
- 批准号:
7887611 - 财政年份:2010
- 资助金额:
$ 41.86万 - 项目类别:
Development of Vaccines against Clostridium difficile Infection
艰难梭菌感染疫苗的研制
- 批准号:
7903007 - 财政年份:2010
- 资助金额:
$ 41.86万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 41.86万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 41.86万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 41.86万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 41.86万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 41.86万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 41.86万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 41.86万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 41.86万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 41.86万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 41.86万 - 项目类别:
Continuing Grant